60results about "Complement proteins" patented technology

An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The present invention relates to a chimeric construct comprising i) an interleukin 2 (IL2) moiety and ii) the beta chain of C4b-binding protein (C4BPβ) or at least one fragment or functional variant thereof capable of forming a dimeric protein.

The invention relates to generally to the field of oncology. Provided herein is a method for detecting for detecting and classifying nasopharyngeal cancer.

The present application relates to a fusion protein of a biopolymer target-specific complement inhibitor, comprising: (i) the extracellular domain of CRIg, (ii) a complement regulatory domain, and (iii) an enhancer domain, as well as methods for producing and using the fusion protein, and pharmaceutical compositions containing the fusion protein. The fusion protein not only has significant targeted complement inhibitory effects, but can also promote increased drug formation and / or production for the treatment and prevention of various human diseases associated with abnormal complement activation.

The disclosure provides modified complement 3d (C3d), compositions containing modified C3d, and methods of using the C3d compositions to treat diseases and disorders, for examples, disease and disorders characterized by evasion of immune surveillance and / or tumor-induced immunosuppression (e.g., multiple myeloma and other plasma cell malignancies).

An isolated antigen binding protein, which includes at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region and a method to encode an isolated nucleic acid molecule. A vector with the nucleic acid molecule. A cell with the nucleic acid molecule. A pharmaceutical composition with the isolated antigen binding protein. A method for preventing, alleviating or treating a C5-related disease or disorder. A method for detecting C5 in a sample.

The present invention relates to an antibody that specifically binds to complement C5, and a fusion protein thereof. The present invention also relates to a polynucleotide encoding the antibody or the fusion protein, an expression vector, and a host cell, and a pharmaceutical composition thereof, and a method and use for treating C5 protein-related diseases.

A protein polymer and a production process therefor. The protein polymer is obtained by means of stimulating MSCs, lysing same, and separating and purifying same. The protein polymer has a strong capability to repair oxidative damage, and thus can reduce the range of cerebral infarction, improve neural functions, inhibit the level of neuroinflammation, and increase the number of surviving neurons.

The disclosure relates to a non-human animal that express a human or chimeric (e.g., humanized) CFB protein and methods of use thereof. The disclosure further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals comprising the non-human animal genome or the humanized CFB gene. The non-human animals obtained in present disclosure successfully express human or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert functions similar to those in the human. Moreover, the non-human animals obtained in present disclosure maintain intact renal function status and normal blood biochemical parameters. Notably, these non-human animals do not result in the potential pathologies observed in some other transgenic mice known in the art.

Present invention relates to novel antibodies and their use in an improved method of determining and detecting C4d.

An isolated polynucleotide comprising a nucleotide sequence encoding a codon-optimised Complement Factor I (CFI).

Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.

The present invention relates to the treatment of cancer and to the prevention of cancer growth and / or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and / or cancers that develop and / or persist by evading host immune surveillance and / or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

A promoter comprising (i) a nucleotide sequence having at least 70% identity to SEQ ID NO: 4 or 17 and wherein the promoter has a length of about 1.1 kb or less.

Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

A fusion protein is provided having a structure A-L-B, wherein: A comprises a sequence that has at least 90% similarity to SEQ ID NO :1; L comprises a linker or a chemical bond; B comprises a sequence that has at least 90% similarity to SEQ ID NO:2. Also provided are medical devices at least partially coated with the fusion protein and uses of the fusion protein.

The present invention relates to a method for stabilizing a fast decay component C3bBb complex of a bypass pathway of a complement system as well as a stabilized C3bBb complex and its use.

The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.

The present invention provides compounds and compositions for inhibiting complement-mediated damage to cells, tissues, or organs. [Solution] The present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. Furthermore, it provides methods for using cell-reactive compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. Furthermore, it provides methods for using long-acting compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides targeted compstatin analogs and compositions comprising targeted compstatin analogs.

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.

Provided is the use of urinary C5b-9 (uC5b-9) as a highly accurate and superior biomarker well correlated with complement activity in local tissues affected by complement-mediated diseases (e.g., those with a kidney damage component). The biomarker is useful, for example, in treating and / or monitoring such complement-mediated diseases, using complement inhibitors targeted to such local tissues affected by the diseases, without systemic complement inhibition.

The present invention provides for N-terminal peptide fragments for complement regulation, their use for the treatment of complement-mediated diseases, and their use in methods of modulation of the complement system.

The present disclosure relates to soluble complement receptor type 1 variants and uses thereof.

Gene therapy treatments are provided for complement-mediated and complement-associated disorders, particularly chronic inflammatory conditions, and more particularly those associated with an overactive complement C3b feedback cycle. [Solution] An isolated polynucleotide is provided comprising a nucleotide sequence encoding complement factor I (CFI), wherein the nucleotide sequence has at least 85% sequence identity to a specific sequence.

A protein polymer and a use thereof in the treatment of Alzheimer's disease. The protein polymer is obtained by stimulating MSCs, and then lysing the MSCs and performing separation and purification. The protein polymer has a strong oxidative damage repair ability, can improve Alzheimer's disease-related biomarker abnormalities, and has a significant treatment effect on Alzheimer's disease.

Compstatin analogues having improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)) (SEQ ID NO: 1) are described, in particular compstatin analogues that additionally possess useful physicochemical properties, such as increased solubility. These analogues include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing solubility, such as the introduction of charged or polar amino acids at position 9 and / or the introduction of N- and / or C-terminal sequences.

The invention belongs to the technical field of biology, and discloses a protein polymer derived from stem cell lysate obtained through ultrasonic stress culture and a preparation method and application of the protein polymer. The inventor finds out that the protein polymer obtained by cracking, separating and purifying stem cells after ultrasonic stimulation culture has a good cell injury repairing effect, is expected to be used for treating neurodegenerative diseases, cerebral apoplexy, arthritis, post-traumatic recovery, autism, enteritis, depression, pulmonary fibrosis and the like, and particularly has a good application prospect in treatment of neurodegenerative diseases, cerebral apoplexy, arthritis, post-traumatic recovery, autism, enteritis, depression, pulmonary fibrosis and the like. The neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), cerebrovascular disease, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), different types of spinal cerebellar ataxia (SCA).

The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.